When the call about a new stomach or esophageal patient comes our team is ready to help. #teamwork

Really nice to see important data out. Been using dosing since presented at @ASCO 2019. Efficacy of Reduced-Intensity Chemotherapy Among Older and Frail Patients With Advanced Gastroesophageal... https://t.co/S5VcFu2Kbe via @JAMAOnc part of @JAMANetwork

ctDNA in UGI malignancies. It was a pleasure to contribute with this opinion paper alongside my mentor. Many thanks Dr @LizzySmyth1 for this opportunities and many others more! https://t.co/4IvOujM3ej

DDF and CancerCare will jointly launch the first-ever helpline dedicated to #stomachcancer patients, their families, caregivers, and those who've lost loved ones to the disease. Read the press release at https://t.co/Yg4q1JnzEc. #DebbiesDreamFoundation #CancerCare #PatientSupport

Really do enjoy caring for #stomach and #esophageal cancer patients. Patient dropped off new mascot for our gastroesophageal program. @CancerMgh

Now online in @CD_AACR: Determinants of Response and Intrinsic Resistance to PD-1 Blockade in #MicrosatelliteInstability-High #GastricCancer by Jeeyun Lee, @KlempnerSam, and colleagues #SamsungMedicalCenter @MGHCancerCenter #Immunotherapy

We have partnered with @StoCANcer to create a Bag It Bag that includes specific information about stomach cancer. You can order Hope In a Bag here: https://t.co/l3ndI80agt. #stomachcancer #fightthefear #cancer #hcsm

Really excellent review on intratumoral heterogeneity in @NatureMedicine . Important in CIN gastroesophageal cancers. https://t.co/zVHA7wFSOu -- text https://t.co/lQoxs0TVCr

Look at this critical review article by @LizzySmyth1 @ValeGambardella and @tfleitask in @Annals_Oncology on Checkpoint inhibitors for gastroesophageal cancers: Dissecting heterog...

Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer

Nice paper in @Gut_BMJ Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing

Nice #GI21 @ASCO_pubs abstr from great Rad-Onc resident Daniel Kim showing Increased T-cell receptor repertoire diversity predicts better overall survival in GI Cancers, including #GEA. @TedHong9 @MGHCancerCenter @Mark_Cobbold

Young-Onset Esophageal Cancer Rapidly Increasing | MedPage Today: now this :(

It's #StomachCancerAwareness month! Be sure to follow MGH Gastroesophageal Cancer Center (@CancerMgh) for more information, resources, and research on stomach and esophageal cancers! #notalone #cancer #cancercare #CancerResearch #oncology #medtwitter #MedStudentTwitter #oncology

Preprint. Results and molecular correlates from neoadjuvant induction FOLFIRINOX followed by chemoradiation and surgery for gastroesophageal adenocarcinomas. @TedHong9 @MGHCancerCenter Pilot data for #ctDNA in neoadj @pashtoonkasi

More data for this targeted population. @Gut_BMJ EGFR amplification and outcome in REAL3 (EOX +/- Panitumumab) for advanced gastro-oesophageal cancers. @LizzySmyth1 @DocCatenacci @SteveMaronMD

Still time to register for this great virtual #stomach and #esophageal research meeting led by @targetcancer and @BassLab_DFCI Link below. Always a great lineup @OncoAlert

It's not too late to register! Inaugural 1st Hope Webcast on November 7th, 2020 at 10am PST! https://t.co/BFEyjnoqTN #StomachCancer #HopeForStomachCancer #Webinar #Register

Morphologic and molecular analysis of early‐onset gastric cancer https://t.co/3kMl27R6k7 #cdh1 #nostomachforcancer @SoniaKupfer

If you have ascites we have an ongoing effort and to make models from your cancer cells to study cancer dependencies and vulnerabilities to ultimately improve therapies. @CancerDepMap @StomachCancer_ @NoStomach4Cancr @GastricCancerFD @count_me_in @StoCANcer